These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33264288)

  • 1. Trade-offs between cost and accuracy in active case finding for tuberculosis: A dynamic modelling analysis.
    Cilloni L; Kranzer K; Stagg HR; Arinaminpathy N
    PLoS Med; 2020 Dec; 17(12):e1003456. PubMed ID: 33264288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xpert
    Kohli M; Schiller I; Dendukuri N; Dheda K; Denkinger CM; Schumacher SG; Steingart KR
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012768. PubMed ID: 30148542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF.
    Orlando S; Triulzi I; Ciccacci F; Palla I; Palombi L; Marazzi MC; Giuliano M; Floridia M; Mancinelli S; Mutemba E; Turchetti G
    PLoS One; 2018; 13(7):e0200523. PubMed ID: 30024890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector.
    Lee DJ; Kumarasamy N; Resch SC; Sivaramakrishnan GN; Mayer KH; Tripathy S; Paltiel AD; Freedberg KA; Reddy KP
    PLoS One; 2019; 14(7):e0218890. PubMed ID: 31265470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microscopic observation drug-susceptibility assay vs. Xpert
    Wikman-Jorgensen PE; Llenas-García J; Pérez-Porcuna TM; Hobbins M; Ehmer J; Mussa MA; Ascaso C
    Trop Med Int Health; 2017 Jun; 22(6):734-743. PubMed ID: 28380276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serological testing versus other strategies for diagnosis of active tuberculosis in India: a cost-effectiveness analysis.
    Dowdy DW; Steingart KR; Pai M
    PLoS Med; 2011 Aug; 8(8):e1001074. PubMed ID: 21857810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and Consequences of Using Interferon-γ Release Assays for the Diagnosis of Active Tuberculosis in India.
    Little KM; Pai M; Dowdy DW
    PLoS One; 2014; 10(4):e0124525. PubMed ID: 25918999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs and cost-effectiveness of a comprehensive tuberculosis case finding strategy in Zambia.
    Jo Y; Kagujje M; Johnson K; Dowdy D; Hangoma P; Chiliukutu L; Muyoyeta M; Sohn H
    PLoS One; 2021; 16(9):e0256531. PubMed ID: 34499668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda.
    Walusimbi S; Kwesiga B; Rodrigues R; Haile M; de Costa A; Bogg L; Katamba A
    BMC Health Serv Res; 2016 Oct; 16(1):563. PubMed ID: 27724908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of the Xpert® MTB/RIF assay for tuberculosis diagnosis in Brazil.
    Pinto M; Steffen RE; Cobelens F; van den Hof S; Entringer A; Trajman A
    Int J Tuberc Lung Dis; 2016 May; 20(5):611-8. PubMed ID: 27084814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.
    Theron G; Peter J; van Zyl-Smit R; Mishra H; Streicher E; Murray S; Dawson R; Whitelaw A; Hoelscher M; Sharma S; Pai M; Warren R; Dheda K
    Am J Respir Crit Care Med; 2011 Jul; 184(1):132-40. PubMed ID: 21493734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling.
    Dowdy DW; Houben R; Cohen T; Pai M; Cobelens F; Vassall A; Menzies NA; Gomez GB; Langley I; Squire SB; White R;
    Int J Tuberc Lung Dis; 2014 Sep; 18(9):1012-8. PubMed ID: 25189546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert
    Pallas SW; Courey M; Hy C; Killam WP; Warren D; Moore B
    Appl Health Econ Health Policy; 2018 Aug; 16(4):537-548. PubMed ID: 29862440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using molecular testing and whole-genome sequencing for tuberculosis diagnosis in a low-burden setting: a cost-effectiveness analysis using transmission-dynamic modelling.
    Mugwagwa T; Abubakar I; White PJ
    Thorax; 2021 Mar; 76(3):281-291. PubMed ID: 33542086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential impact of urine-LAM diagnostics on tuberculosis incidence and mortality: A modelling analysis.
    Ricks S; Denkinger CM; Schumacher SG; Hallett TB; Arinaminpathy N
    PLoS Med; 2020 Dec; 17(12):e1003466. PubMed ID: 33306694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial.
    Durovni B; Saraceni V; van den Hof S; Trajman A; Cordeiro-Santos M; Cavalcante S; Menezes A; Cobelens F
    PLoS Med; 2014 Dec; 11(12):e1001766. PubMed ID: 25490549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach.
    Langley I; Lin HH; Egwaga S; Doulla B; Ku CC; Murray M; Cohen T; Squire SB
    Lancet Glob Health; 2014 Oct; 2(10):e581-91. PubMed ID: 25304634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the Xpert MTB/RIF on the detection of pulmonary tuberculosis cases and rifampicin resistance in Shanghai, China.
    Wu Z; Rueda ZV; Li T; Zhang Z; Jiang Y; Sha W; Yu F; Chen J; Pan Q; Shen X; Yuan Z
    BMC Infect Dis; 2020 Feb; 20(1):153. PubMed ID: 32070292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.